TriangleDurvalumab (NCT06503614)
Durvalumab trial for Non-muscle Invasive Bladder Cancer (NCT06503614). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with high-grade non-muscle-invasive bladder cancer after BCG treatment who cannot undergo or decline bladder removal. Visible papillary tumors must be removed; carcinoma in situ may remain. Prior checkpoint therapy is excluded.
The idea: combine durvalumab and monalizumab infusions every four weeks for up to one year. They block PD-L1 and NKG2A immune brakes, respectively, to support immune-cell attack. Separate groups have carcinoma in situ or papillary disease without it. Researchers assess response and safety.
This phase 2 study plans 60 patients. John Sfakianos leads five recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.